“In Situ” Liver Disease & Transplant

What Does “In Situ” Mean?

Pathologists use the term in situ when cells have become abnormal — sometimes called intraepithelial neoplasia or high-grade dysplasia — but remain confined to the epithelial layer and have not yet invaded deeper tissues or blood vessels.^{[3], [4]}

• In situ = “on site” — the abnormal clone is still fenced in.
• Not benign, not yet invasive cancer — best thought of as a precancerous or pre-invasive stage.
• Higher risk of progression than normal tissue, especially if inflammation and fibrosis persist.

In Situ Changes in the Liver

In cirrhotic or chronically inflamed livers, a spectrum of pre-cancerous lesions can appear, including dysplastic nodules and intraepithelial neoplasia along bile ducts.^{[1], [2], [4]}

• Dysplastic nodules in cirrhosis, which can evolve toward early HCC.
• Biliary intraepithelial neoplasia (BilIN), a recognized precursor along the path to cholangiocarcinoma.^[4]
• Gastrointestinal intraepithelial neoplasia in adjacent structures (stomach, intestine) that may coexist with liver disease and share risk factors such as chronic inflammation and viral hepatitis.^[4]

On imaging, these lesions are often subtle; definitive classification usually comes from pathology after biopsy, resection, or transplant. Guidelines emphasize that patients with cirrhosis or chronic hepatitis should undergo structured surveillance to detect these changes early, before invasive cancer has a chance to declare itself.^{[1], [2]}

Why “In Situ” Disease Matters for Transplant

Liver transplantation does not just remove cirrhosis; it also removes the microscopic “garden” where in situ and early cancers can arise. Modern transplant and liver-cancer guidelines use tumor size, number, and vascular invasion — along with overall liver function — to decide when transplant offers the best chance of long-term survival.^{[1], [2], [5]}

If a lesion is truly in situ or very early, the transplant team may have more options:

• Curative local therapies such as ablation or resection, with transplant reserved as backup.
• Listing for transplant under HCC criteria if the risk of progression is high and the patient meets size/number cut-offs.
• Close observation when pathology shows atypia or low-grade dysplasia but not definite cancer.

From the patient’s perspective, in situ disease feels like living with a small shadow on the scan: it is not yet a storm, but it changes the entire forecast.

Surveillance & Treatment Options

For people with cirrhosis or chronic hepatitis, expert societies recommend regular ultrasound ± AFP every 6 months to screen for HCC, with cross-sectional imaging when something suspicious appears.^{[1], [2], [5]}

• Imaging surveillance: ultrasound, CT, or MRI to follow nodules over time.
• Biopsy in selected cases: when imaging cannot clearly distinguish high-grade dysplasia from early cancer.
• Locoregional therapy: radiofrequency ablation, microwave ablation, or embolization for early HCC within transplant criteria.^[5]
• Optimization of underlying liver disease: antiviral therapy for hepatitis B or C, alcohol cessation, metabolic risk management, and vaccination where appropriate.^[1]

Questions to Ask Your Transplant Team

If your pathology or imaging report mentions terms like “dysplastic nodule,” “intraepithelial neoplasia,” or “in situ change,” these questions can help frame the discussion:

• “Is this definitely cancer, or pre-cancer?”
• “What is the risk that this lesion progresses over the next 6–12 months?”
• “How does this finding affect my transplant candidacy or timing?”
• “Should we consider local treatment now, or continued surveillance?”
• “What lifestyle or medical steps can I take to reduce my overall cancer risk?”

The goal is not to turn you into a pathologist, but to help you understand where your story sits along the spectrum — from purely in situ changes to fully invasive cancer — so you and your team can choose the safest path forward together.